成人特应性皮炎系统免疫调节药物的比较安全性
基于人群的索赔数据研究纳入多达232,611例接受系统药物治疗的成人特应性皮炎患者,比较严重细菌和机会性感染风险。甲氨蝶呤和环孢素6个月风险最低,泼尼松、硫唑嘌呤和霉酚酸酯风险相对升高;度普利尤单抗使用者风险未增加。
要点
- 环孢素和甲氨蝶呤6个月严重感染风险最低。
- 泼尼松、硫唑嘌呤和霉酚酸酯风险相对甲氨蝶呤升高。
- 度普利尤单抗使用者未见严重感染风险增加。
核心结论
- 在成人特应性皮炎患者中,环孢素和甲氨蝶呤的6个月严重感染风险最低。
- 与甲氨蝶呤相比,泼尼松、硫唑嘌呤和霉酚酸酯的严重感染风险增加。
- 度普利尤单抗使用者未观察到严重感染风险增加。
研究设计与样本
- 基于人群的索赔数据研究,纳入接受系统药物治疗的成人特应性皮炎患者,最多232,611例符合条件。
- 通过国际疾病分类诊断代码计算导致住院的严重细菌和机会性感染发生率。
- 采用1:1倾向评分匹配后计算相对风险(RR)。
主要发现
- 系统非生物制剂治疗患者严重感染发生率为每1,000例患者7.53(7.18-7.89)风险。
- 光疗患者严重感染发生率为每1,000例患者7.38(5.68-9.57)风险。
- 度普利尤单抗使用者严重感染发生率为每1,000例患者2.6(0.45-14.3)风险。
- 匹配后,环孢素6个月风险显著降低(RR 0.87),泼尼松(RR 1.78)、硫唑嘌呤(RR 1.89)和霉酚酸酯(RR 3.31)风险增加(均相对于甲氨蝶呤)。
- 度普利尤单抗使用者未显示风险增加(RR 0.33,95%CI 0.03-3.20)。
关键数值与推荐
- 严重感染定义为导致住院的细菌和机会性感染,基于国际疾病分类诊断代码。
- 6个月相对风险以甲氨蝶呤为参照:环孢素RR 0.87;泼尼松RR 1.78;硫唑嘌呤RR 1.89;霉酚酸酯RR 3.31。
- 度普利尤单抗RR 0.33(95%CI 0.03-3.20)。
临床怎么用
- 在成人特应性皮炎系统治疗选择中,可优先考虑甲氨蝶呤或环孢素以降低严重感染风险。
- 使用泼尼松、硫唑嘌呤或霉酚酸酯时应警惕严重感染风险升高。
局限性
- 部分比较涉及小样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe atopic dermatitis (AD) is increasingly treated with systemic immunomodulatory drugs, yet their safety is unclear. OBJECTIVE: We evaluated the comparative risk of serious bacterial and opportunistic infections among patients with severe AD using systemic immunomodulatory medications in routine care. METHODS: In a population-based claims data study, we identified adult patients with AD who were treated with systemic drugs. The incidence of serious bacterial and opportunistic infections leading to hospitalization was computed by using International Classification of Disease diagnosis codes. Relative risks (RRs) were computed after 1-to-1 propensity score matching. RESULTS: Up to 232,611 patients with AD were eligible. The incidence of serious infections was 7.53 (7.18-7.89) risk per 1,000 patients among systemic nonbiologic-treated patients, 7.38 (5.68-9.57) risk per 1,000 patients among phototherapy-treated patients, and 2.6 (0.45-14.3) risk per 1,000 patients among dupilumab users. After matching, cyclosporine had a significantly reduced 6-month risk (RR 0.87) and prednisone (RR 1.78), azathioprine (RR 1.89), and mycophenolate (RR 3.31) showed increased risks compared with methotrexate. A small number of dupilumab users showed no increased risk (RR 0.33, 95% confidence interval 0.03-3.20). LIMITATIONS: Some comparisons involved small population sizes. CONCLUSION: In this population-based study of adult AD patients, cyclosporine and methotrexate have the lowest 6-month risks of serious infections. Increased risks were observed for prednisone, azathioprine, and mycophenolate relative to methotrexate.
引用
- Schneeweiss MC, Perez-Chada L, Merola JF, et al. Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis. J Am Acad Dermatol. 2019. PMID: 31158390. doi:10.1016/j.jaad.2019.05.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。